# Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer

> **NCT02600949** · PHASE1 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 300 (estimated)

## Conditions studied

- Metastatic Colorectal Adenocarcinoma
- Metastatic Pancreatic Ductal Adenocarcinoma
- Stage IV Colorectal Cancer AJCC v7
- Stage IV Pancreatic Cancer AJCC v6 and v7
- Stage IVA Colorectal Cancer AJCC v7
- Stage IVB Colorectal Cancer AJCC v7

## Interventions

- **DRUG:** Imiquimod
- **BIOLOGICAL:** Pembrolizumab
- **BIOLOGICAL:** Sotigalimab
- **BIOLOGICAL:** Synthetic Tumor-Associated Peptide Vaccine Therapy
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Magnetic Resonance Imaging

## Key facts

- **NCT ID:** NCT02600949
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2016-05-11
- **Primary completion:** 2027-05-31
- **Final completion:** 2027-05-31
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-04-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02600949

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02600949, "Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02600949. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*